LIVSMED

Market position

LivsMed positions itself as offering articulating dexterity comparable to robotic surgical platforms at lower cost and with retained tactile feedback, and states it is the only company offering 5mm wristed articulating instruments. At its KOSDAQ debut its market capitalization surpassed ₩1.4 trillion (approximately $1 billion), which the company characterized as medtech unicorn status.

The company emphasizes articulation and wristed dexterity in handheld instruments without additional capital equipment or lead time, retention of tactile feedback that robotic systems do not provide, the only 5mm wristed articulating instrument line, the first fully-articulating double-jointed clip applier, and the only 90-degree articulating vessel sealer.

Technology

ArtiSential instruments use double-jointed end tools with an ergonomic grip that translate the surgeon's wrist and hand motion into full articulation and 360-degree rotation while preserving tactile feedback. ArtiSeal adds 90-degree articulating vessel sealing and cutting; the clip applier applies the same double-jointed articulation. The ArtiSential 5 line reduces instrument size by 40% for greater visibility and allows use of smaller trocars. STARK is a robot-assisted surgical system whose telesurgery capability was demonstrated over long-distance connectivity using Sovato's platform.

Go-to-market

The company sells through a direct sales force targeting surgeons across general, bariatric, gynecological, thoracic and colorectal specialties, supported by the AcuityMD commercial platform for surgeon targeting, and markets at clinical conferences such as SAGES, ASCRS and SRS annual meetings.

Surgeons and surgical teams performing laparoscopic and robotic minimally invasive procedures across general, bariatric, gynecologic, thoracic and colorectal specialties, in hospital operating rooms and ambulatory surgery centers.

Geography

Headquartered in Seoul, Republic of Korea, with a U.S. subsidiary in San Diego, California, and a listed office in Seongnam-si. Products are sold in Korea and the United States, and the company works with physicians internationally, including in Germany.

History

The company was founded in South Korea by Dr. Jung Joo Lee around the concept of making articulating technology available to every laparoscopic surgeon. ArtiSential launched in Korea in 2018 and entered the U.S. market in 2019, where it received the Red Dot Design Award and recognition from the Society of American Gastrointestinal and Endoscopic Surgeons. In 2023 the company adopted AcuityMD's commercial platform to support U.S. commercialization. It extended the product line with ArtiSential 5 in 2024, the ArtiSential Clip Applier and ArtiSeal in early 2025, demonstrated telesurgery with its STARK robot in July 2025, and completed a KOSDAQ IPO announced in January 2026.

Risks & controversies

The STARK robot-assisted surgical system is not approved for use and not for sale in the United States. Company disclosures cite risks including regulatory approval processes in Korea, the U.S. and other markets, reimbursement policies, clinical outcomes, manufacturing and supply-chain considerations, competitive dynamics, intellectual property protection and foreign exchange fluctuations.